Alumis Reports Positive Phase 3 Data With Envudeucitinib
Alumis (ALMS) reported Phase 3 data for envudeucitinib, showing a 54% PASI 100 response rate at Week 48. The company aims for a 2026 NDA submission. Shares rose 3.49% in pre-market trading to $7.21. According to the CEO, the results support its potential as a leading oral therapy for plaque psoriasis.
How this was made
The 30-second read
Why it matters
The Phase 3 results represent the first publicly disclosed efficacy data for envudeucitinib, a key milestone before NDA submission.
Market read
The announcement is a primary disclosure that can move the stock and influence sentiment in the dermatology biotech space.
What to watch
Potential competition from existing biologics and the need for a successful NDA filing later in 2026.
Background
Alumis (ALMS) is a Nasdaq‑listed biotech developing oral treatments for moderate‑to‑severe plaque psoriasis.
Ticker impact
Alumis released positive Phase 3 data for envudeucitinib, showing a 54% PASI‑100 response at Week 48 and its shares rose 3.49% pre‑market.
upward pressure as the market prices in the strong Phase 3 outcome
Phase 3 data are material for a biotech; the 54% PASI‑100 rate is a strong efficacy signal and the stock already moved up on the news.
Market effects
Positive psoriasis trial data may lift other biotech and dermatology‑focused companies.
Primarily U.S. biotech investors; limited broader regional effect.
Adds confidence to the pipeline of oral psoriasis therapies worldwide.
Counterpoint
If the data do not translate into regulatory approval or commercial uptake, the rally could be short‑lived.
Key entities
- personMartin Babler
CEO of Alumis, quoted on regulatory execution and NDA timeline.
